Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Prof. Lutfu Hanoglu, MD

Status: Completed

Conditions: Alzheimer Type Dementia; Alzheimer's Disease (AD)

Treatments: Behavioral: Ketoflex 12/3 Diet

Study type: Interventional

Funder types: Other

Identifiers

NCT06898424

ALZ23992

Details and patient eligibility

About

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Enrollment: 60 patients

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age between 50-85 years
• Clinical Dementia Rating (CDR) score of 0.5 or 1
• Diagnosis of Alzheimer's disease (AD) according to NINCDS-ADRDA criteria

Exclusion criteria

• Alcohol and/or substance dependence
• Diagnosis of chronic renal failure
• Diagnosis of another neuropsychiatric disorder
• Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Ketoflex 12/3 Diet Group

Experimental group

Description:

Participants follow the Ketoflex 12/3 dietary protocol.

Treatment:

Behavioral: Ketoflex 12/3 Diet

Control Group

No Intervention group

Description:

Participants continue their usual diet with no modifications